Back

Do valve hemodynamic function and durability matter?

1 September 2019 (18:36 - 18:45)
Organised by:
Congress Presentation Part of: Impact of low-surgical-risk TAVI trials on clinical decision making Diseases of the Aorta, Other ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Philippe Pibarot

Quebec Heart and Lung Institute, Quebec (Canada)

5 More presentations in this session

Presentation thumbnail
Welcome and introductions
Professor L. Pierard (Liege, BE)
Presentation thumbnail
Asymptomatic patients at risk with severe aortic stenosis
Professor L. Pierard (Liege, BE)
Presentation thumbnail
Clinical case - A low surgical risk patient undergoing TAVI
Professor T. Modine (Bordeaux, FR)
Presentation thumbnail
What is the impact on clinical practice of low-risk TAVI trials?
Professor G. Tarantini (Padova, IT)
Presentation thumbnail
Questions and answers and panel discussion
Professor L. Pierard (Liege, BE)

Access the full session

Session thumbnail
Impact of low-surgical-risk TAVI trials on clinical decision making

The Event

Event poster

ESC Congress 2019

1 September 2019 18:36 CET
You may be interested in
thumbnail
Congress Presentation
Long-term structural valve deterioration after TAVI: insights from the European Valve Durability TAVI registry
30 August 2024
thumbnail
Congress Presentation
Impact of right ventricular function and ventriculo-arterial coupling in prognosis after percutaneous edge-to-edge mitral repair
27 August 2021
thumbnail
Congress Session
Personalised approach to decompensated heart failure
17 May 2025
thumbnail
Congress Presentation
The influence of the valve expansion on the hemodynamic outcome in valve-in-valve transcatheter aortic valve replacement
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources